GlucoseTech | Continuous Glucose Monitoring (CGM) Education for Healthcare Providers

Exploring innovations that make continuous glucose monitoring (CGM) easier to use, transforming diabetes management for healthcare providers (HCPs) and patients.

Dexcom President and CEO Jake Leach explains how advances including G7 15 Day, Smart Basal, Smart Bolus, and EHR integration are helping clinicians optimize diabetes treatment. Live from ADA 2026, he discusses the CONNECT Study, CGM-guided nutrition, and how real-time glucose insights can support people with type 1 diabetes, type 2 diabetes, and prediabetes.

--

Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information.

Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.

Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. “Dexcom" refers to the Dexcom CGM. Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. To use Share/Follow the smartphone must be within 33 feet of the Dexcom G7. The Dexcom G7Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy. G7 15 Day is only for adults 18+.

This guest is a paid spokesperson for Dexcom.

Dexcom, Dexcom Clarity, Dexcom Follow, Dexcom One, Dexcom Share, Stelo, any related logos and design marks are either registered trademarks or trademarks of Dexcom, Inc. in the United States and/or other countries. ©2026 Dexcom, Inc. All rights reserved.

STELO IMPORTANT INFORMATION: Consult your healthcare provider before making any medication adjustments based on your sensor readings and do not take any other medical action based on your sensor readings without consulting your healthcare provider. Do not use if you have problematic hypoglycemia. Failure to use Stelo and its components according to the instructions for use provided and to properly consider all indications, contraindications, warnings, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence. If your sensor readings are not consistent with your symptoms, a blood glucose meter may be an option as needed and consult your healthcare provider. Seek medical advice and attention when appropriate, including before making any medication adjustments and/or for any medical emergency.

BRIEF SAFETY STATEMENT: Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at CGM Safety Information | Dexcom | Dexcom and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. Dexcom, Dexcom Clarity, Dexcom Follow, Dexcom One, Dexcom Share, Stelo, and any related logos and design marks are either registered trademarks or trademarks of Dexcom, Inc. in the United States and/or other countries.

Exploring workflows that make continuous glucose monitoring (CGM) simple to implement, transforming diabetes management for healthcare providers (HCPs).

Pediatric endocrinologist Dr. Anita Swamy explains why modern diabetes technology is reshaping diabetes management for both type 1 diabetes and type 2 diabetes patients. Drawing on years of clinical experience, she walks through how HCPs and primary care teams can integrate CGM insights into routine practice, improve blood sugar monitoring, and support better metabolic health outcomes.

--

Disclaimer:

This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. Reimbursement and coverage may vary by payer, plan, and care setting. References supporting clinical claims are available in the associated show notes; results may differ across patient populations. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. Comparative product statements are based on publicly available product labeling and may vary by device and region. For complete safety information, go to dexcom.com/safety-information. Fingersticks are required for diabetes treatment decisions if symptoms or expectations do not match readings. Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. “Dexcom" refers to the Dexcom CGM. Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. To use Share/Follow the smartphone must be within 33 feet of the Dexcom G7. The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy. G7 15 Day is only for adults 18+. This guest is a paid spokesperson for Dexcom. The views expressed by speakers are based on individual clinical experience and may not be generalizable. 

Brief Safety Statement:

Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. Continuous glucose monitoring (CGM) should be used as part of a broader diabetes management plan under the guidance of a qualified healthcare provider.  Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S. and may be registered in other countries. Stelo Important Information: The Stelo Glucose Biosensor System is an overthecounter (OTC) integrated Continuous Glucose Monitor (iCGM) intended for people 18 years and older not on insulin. Stelo may help users better understand how lifestyle and behavior modification, including diet and exercise, impact glucose excursion. Users should not take medical action based on Stelo readings without consultation with a qualified healthcare professional. If sensor readings do not match symptoms, a blood glucose meter may be an option, and users should consult their healthcare provider. For complete safety information, visit stelo.com/safety-information.

Can continuous glucose monitoring improve outcomes for type 2 diabetes patients not on insulin? In this episode of the GlucoseTech podcast, host Cher Pastore, is joined by Keri Leone, from Dexcom Medical Affairs to unpack the CONNECT Trial presented at ADA 2026. This landmark randomized controlled trial showed Dexcom G7 CGM delivered a 1.6% A1C reduction and doubled time in range in primary care settings, with 97% voluntary wear time. Discover how this evidence is set to reshape diabetes management and expand CGM access for healthcare providers and patients across diverse populations.

Dexcom CONNECT Study: https://bit.ly/4whGLoL

--

Disclaimer:

Brief Safety Statement:                                                                                                       

Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency. Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries. Stelo Important Information: The Stelo Glucose Biosensor System is an over‑the‑counter (OTC) integrated Continuous Glucose Monitor (iCGM) intended for people 18 years and older not on insulin. Stelo may help users better understand how lifestyle and behavior modification, including diet and exercise, impact glucose excursion. Users should not take medical action based on Stelo readings without consultation with a qualified healthcare professional. If sensor readings do not match symptoms, a blood glucose meter may be an option, and users should consult their healthcare provider. For complete safety information, visit stelo.com/safety-information. MAT#15325

How did Continuous Glucose Monitoring (CGM) transform diabetes care in 2025? In this highlights episode of Real-Time Real Talk, Cher revisits standout moments from the year, with conversations exploring how CGM reshaped diabetes management. Featuring insights from Dr. Tom Grace, Dr. Bill Polonsky, Emily Cornelius, RD, David Doriguzzi, Grant Ovzinsky, Lance Bass, Rachel Sood, and Jami Klein, this episode brings together clinical expertise, lived experience, and real-world perspectives. 

----

Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go todexcom.com/safety-information.

Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.

Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer. Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility. “Dexcom" refers to the Dexcom CGM. Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. To use Share/Follow the smartphone must be within 33 feet of the Dexcom G7. The Dexcom G7Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy. G7 15 Day is only for adults 18+.

This guest is a paid spokesperson for Dexcom.

Brief Safety Statement:          

Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.

Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.

STELO IMPORTANT INFORMATION: Consult your healthcare provider before making any medication adjustments based on your sensor readings and do not take any other medical action based on your sensor readings without consulting your healthcare provider. Do not use if you have problematic hypoglycemia. Failure to use Stelo and its components according to the instructions for use provided and to properly consider all indications, contraindications, warnings, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence. If your sensor readings are not consistent with your symptoms, a blood glucose meter may be an option as needed and consult your healthcare provider. Seek medical advice and attention when appropriate, including before making any medication adjustments and/or for any medical emergency. Patient results may vary.

Why did Dexcom move to a 15-day sensor? Because they listened. In this episode of Real Time Real Talk, host Cher Pastore talks with Grant

----

Disclaimer:

Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.

Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.

Smart devices are sold separately. For a list of compatible smart devices, visit:

“Dexcom" refers to the Dexcom CGM.

Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. To use Share/Follow the smartphone must be within 33 feet of the Dexcom G7.

The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy.

G7 15 Day is only for adults 18+.

This guest is a paid spokesperson for Dexcom.

Brief Safety Statement:                                                                                                       

Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.

Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.

STELO IMPORTANT INFORMATION: Consult your healthcare provider before making any medication adjustments based on your sensor readings and do not take any other medical action based on your sensor readings without consulting your healthcare provider. Do not use if you have problematic hypoglycemia. Failure to use Stelo and its components according to the instructions for use provided and to properly consider all indications, contraindications, warnings, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence. If your sensor readings are not consistent with your symptoms, a blood glucose meter may be an

Endocrinologist Dr. Egils Bogdanovics and Chelsea Lugone join Cher Pastore to break down type 1 diabetes screening and staging: who to screen, how to interpret results, using CGM to prompt action, and current options available to delay progression. Plus practical advice for talking with families and reducing DKA at diagnosis.

--

Disclaimer: This podcast is not approved for CME credit. Every

Fingersticks are required for diabetes treatment decisions if

Dexcom G7 can complete warmup within 30 minutes, whereas other CGM

Smart devices are sold separately. For a list of compatible smart

“Dexcom" refers to the Dexcom CGM.

Compatible smartphone is required to pair a new Dexcom G7 sensor

The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7

G7 15 Day is only for adults 18+.

This guest is a paid spokesperson for Dexcom.

Brief Safety Statement:                                                                                                       

Failure to use the Dexcom Continuous Glucose Monitoring System and

Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are

STELO IMPORTANT INFORMATION: Consult your healthcare provider

How is continuous glucose monitoring (CGM) transforming pregnancy care? In this special episode, maternal-fetal medicine expert Dr. Stacey Ehrenberg and diabetes educator Joy Cornthwaite, RD, join Real-Time Real Talk to break down the latest research from the ADA Conference and share real-world stories of Dexcom G7 in action. Discover how CGM empowers patients and providers, overcomes clinical barriers, and delivers personalized insights for healthier pregnancies and beyond.

Listen now: https://provider.dexcom.com/education-research/podcast

Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information. 

Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.

Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.

Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility.

“Dexcom" refers to the Dexcom CGM.

Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. To use Share/Follow the smartphone must be within 33 feet of the Dexcom G7.

The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy.

G7 15 Day is only for adults 18+.

This guest is a paid spokesperson for Dexcom.

Brief Safety Statement:       

Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and

Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.

STELO IMPORTANT INFORMATION: Consult your healthcare

Only 1 in 5 people with type 2 diabetes on insulin use Continuous Glucose Monitoring (CGM) and for those not on insulin, that number drops to just 5%. With real-time glucose tracking transforming how patients understand and manage their health, why isn’t CGM more widely used? In this live episode from the American Diabetes Association (ADA) Conference, Real-Time Real Talk explores the barriers, breakthroughs, and future of diabetes technology. You'll hear why CGM is gaining traction not just for type 1 diabetes, but also in primary care, prediabetes, and even among the glucose-curious.

--

Disclaimer: This podcast is not approved for CME credit. Every diabetes treatment plan is different, individual results may vary – nothing you hear on this podcast should be considered medical advice. All claims are supported by clinical evidence referenced in the show notes. For clinical study results, please refer to the Dexcom G7 User Guide. For product-related questions, please refer to the instructions for use. For complete safety information, go to dexcom.com/safety-information.

Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.

Dexcom G7 can complete warmup within 30 minutes, whereas other CGM brands require up to an hour or longer.

Smart devices are sold separately. For a list of compatible smart devices, visit: dexcom.com/compatibility.

“Dexcom" refers to the Dexcom CGM.

Compatible smartphone is required to pair a new Dexcom G7 sensor with a compatible Apple Watch. To use Share/Follow the smartphone must be within 33 feet of the Dexcom G7.

The Dexcom G7 Continuous Glucose Monitoring System (Dexcom G7 System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons aged 2 years and older. Dexcom G7 has no limitations for use in pregnancy.

G7 15 Day is only for adults 18+.

This guest is a paid spokesperson for Dexcom.

Brief Safety Statement:                                                                                                       

Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.

Dexcom, Dexcom Follow, Dexcom Clarity, and Dexcom Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.

STELO IMPORTANT INFORMATION: Consult your healthcare provider before making any medication adjustments based on your sensor readings and do not take any other medical action based on your sensor readings without consulting your healthcare provider. Do not use if you have problematic hypoglycemia. Failure to use Stelo and its components according to the instructions for use provided and to properly consider all indications, contraindications, warnings, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence. If your sensor readings are not consistent with your symptoms, a blood glucose meter may be an option as needed and consult your healthcare provider. Seek medical advice and attention when appropriate, including before making any medication adjustments and/or for any medical emergency. Patient results may vary.


MAT-9989

Lance Bass discusses an honest look at misdiagnosis, diabetes stigma, and how real-time Continuous Glucose Monitoring (CGM) transformed his life on this special episode of Real-Time Real Talk recorded live at the American Diabetes Association conference (ADA) in Chicago this June.

When Lance was first diagnosed with type 2 diabetes, it didn’t make sense - he ate well, exercised, and didn’t fit the typical profile. But as his glucose remained high and symptoms worsened, he discovered he actually had LADA (Latent Autoimmune Diabetes in Adults), a slow-progressing form of type 1 diabetes.

Host Cher Pastore, MS, RD, CDCES, BC-ADM sits down with Lance to unpack his journey from misdiagnosis to managing his condition with CGM and advanced diabetes technology.

Lance shares how CGM with the Dexcom G7 transformed his diabetes management, allowing him to see blood sugar levels in real time, avoid dangerous lows, and personalize his food and insulin decisions. They discuss everything from automated insulin delivery systems to blood sugar monitoring tips, glucose sensors, and the mental relief that comes from not having to guess what’s happening in your body.

He also opens up about raising awareness, reducing stigma for young people with diabetes, and why showing his G7 publicly has helped others feel seen and supported.

Whether you're a healthcare provider, parent, or person living with diabetes, this episode offers powerful insight into the life-changing potential of CGM technology and is a must-listen for anyone affected by type 1 diabetes, type 2 diabetes, or prediabetes - including patients, endocrinologists, and primary care providers. The interview offers an honest and insightful look at how biosensor tools like CGM are reshaping diabetes treatment, diabetes education, and metabolic health outcomes.

Even for those not on insulin, Continuous Glucose Monitoring (CGM) is transforming the way HCPs approach diabetes treatment. Cher Pastore, MS, RD, CDCES, BC-ADM and guest David Doriguzzi, a Physician Assistant in endocrinology and internal medicine explore how Dexcom G7 and Stelo are reshaping diabetes management for people with type 1 diabetes, type 2 diabetes, and prediabetes.

Together, they break down how Dexcom’s portfolio provides real-time glucose monitoring, reveals patterns invisible through traditional blood sugar monitoring, and inspire meaningful behavior change.

David shares patient stories that demonstrate how CGM is helping individuals recognize how food, activity and medications impact their diabetes management. He also explains how CGM empowers providers to tailor diabetes education and medication strategies, especially in primary care settings with limited access to endocrinologists. 

Whether you’re managing type 1 diabetes, type 2 diabetes or on the journey to prevent it, this conversation showcases how diabetes technology like CGM can simplify treatment decisions, personalize care, and ultimately make an impact for both patients and providers.